

Major R&D Pipeline

Daiichi Sankyo Group Major Research & Development Pipeline (Development Stage)

July 2010
DAIICHI SANKYO CO., LTD.

Therapeutic Area	Main Existing Product	Phase1	Phase2	Phase3	Application
Cardiovascular diseases	Mevalotin Benicar/Olmetec Azor/Sevikar Welchol Effient/Efient Olmetec Rezaltas Calblock Artist Mevalotin Kremezin Hanp Livalo Sunrhythm Repricor	DB-772d (oral factor Xa inhibitor)	DU-176b(US/EU) (Edoxaban / post surgical VTE / oral factor Xa inhibitor) CS-747(JP) (Prasugrel / anti-platelet agent)	★CS-747(US/EU) (Prasugrel / ACS-MM / anti-platelet agent) DU-176b(US/EU/JP/Asia) (Edoxaban / AF / oral factor Xa inhibitor) DU-176b(US/EU/JP/Asia) (Edoxaban / VTE / oral factor Xa inhibitor)	★CS-8635(US) (Olmesartan, Amlodipine, Hydrochlorothiazide combination) ★CS-8635(EU) (Olmesartan, Amlodipine, Hydrochlorothiazide combination) DU-176b(JP) (Edoxaban / post surgical VTE / oral factor Xa inhibitor)
Diabetes mellitus	Welchol Fastic		CS-1036(JP/Asia) (glucose absorption inhibitor)		
Cancer	Topotecin Krestin	U3-1287(US) (anti-HER3 antibody) CS-1008(JP) (Tigatuzumab / anti-DR5 antibody) CS-7017(JP/Asia) (PPARγ activator)	CS-1008(US/EU/Asia) (Tigatuzumab / anti-DR5 antibody) CS-7017(US/EU) (PPARγ activator) DE-766(JP) (Nimotuzumab / anti-EGFR antibody) ARQ 197(US/EU) (c-Met inhibitor)		
Infectious diseases	Levaquin / Tavanic Banan Cravit	CS-8958(US/EU) (Laninamivir / anti-influenza / co-development with Biota) CS-4771 (Sepsis) <u>DS-8587</u> (Broad spectrum antibacterial agents)		★CS-8958(JP) (Laninamivir / prophylactic /anti-influenza)	★Levofloxacin inj(JP) (new quinolone) CS-8958(JP) (Laninamivir / treatment / anti-influenza)
Bone/Joint diseases	Loxonin Mobic			AMG 162(JP) (denosumab / bone metastases of cancer, osteoporosis / anti-RANKL antibody)	★CS-600G(JP) (Loxoprofen / gel)
Immunological allergic diseases	Zyrtec	CS-0777 (immunomodulator)	SUN13834(US) (chymase inhibitor)		
Others	Venofor Evoxac Omnipaque Omniscan Visipaque Sonazoid Feron Urief		SUN11031(US/EU) (Human ghrelin / cachexia) ★DD-723-B(JP) (Perflubutane / ultrasonic contrast agent)	SUN11031(JP) (Human ghrelin / anorexia nervosa)	KMD-3213(China) (Silodosin / treatment of dysuria associated with benign prostatic hyperplasia) SUN Y7017(JP) (Memantine / Alzheimer's type Dementia)

★Additional indications, new formulations etc.

Change from the announcement in May 2010

New(underline)

DS-8587(Broad spectrum antibacterial agents/P1)

Change of Stage etc.

★CS-8635(Triple combination formulation / US / Approved), ★CS-600G(Loxoprofen / gel / JP /Approved)